Drug Profile


Alternative Names: ddI/HU - Virostatics; Didanosine/hydroxyurea - Virostatics; VS 411

Latest Information Update: 04 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Virostatics
  • Class Antianaemics; Antineoplastics; Antiretrovirals; Dideoxynucleosides; Purine nucleosides; Ribonucleosides; Urea compounds
  • Mechanism of Action DNA synthesis inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 02 Mar 2011 Discontinued - Phase-II for HIV-1 infections in Argentina, Uganda, Russia and Italy (PO)
  • 02 Mar 2011 Efficacy data from a phase II trial in HIV-1 infections released by Virostatics
  • 19 Jul 2010 Efficacy and adverse events data from a phase II trial in HIV-1 infections presented at the 18th International AIDS Conference (IAC-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top